RP1 Plus Nivolumab Is Active, Safe in Advanced Melanoma After Progression on Anti–PD-1 Therapy
Source: OncLive, November 2024
RP1 plus nivolumab generated responses in advanced melanoma that progressed on or after prior anti–PD-1 therapy.
The combination of the HSV-1–based oncolytic immunotherapy RP1 (vusolimogene oderparepvec) and nivolumab (Opdivo) generated responses and had a favorable safety profile in patients with advanced melanoma whose disease progressed on or after prior anti–PD-1 therapy, according to data from the phase 2 IGNYTE trial (NCT03767348).
Findings presented at the 2024 SITC Annual Meeting demonstrated that at a median follow-up of 15.4 months (range, 0.5-47.6), patients treated with RP1 plus nivolumab (n = 140) achieved a confirmed overall response rate (ORR) of 33.6% (95% CI, 25.8%-42.0%) per modified RECIST (mRECIST) 1.1 criteria by blinded independent central review (BICR) assessment. This comprised a complete response (CR) rate of 15.0% and a partial response (PR) rate of 18.6%; the stable disease (SD) and progressive disease (PD) rates were 29.3% and 30.7%, respectively.